Aprea Therapeutics Inc (APRE) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.74 (-1.03%), Market cap $0.01B, 52-week low–high $0.59 ~ $2.08.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Financial statements, price targets, institutional (13F) holdings and related news for Aprea Therapeutics Inc are updated in real time on BlackAll Trade.
Aprea Therapeutics Inc trades at $0.74 (-1.03%). Real-time quotes and charts are available on BlackAll Trade.
Aprea Therapeutics Inc has a market cap of about $0.01B.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pat